Making all the children above average: Ethical and regulatory concerns for pediatricians in pediatric enhancement research

Clinical Pediatrics

Volumn 48, Issue 5, 2009, Pages 472-480

  Berg, Jessica W ^a   Mehlman, Maxwell J ^a   Rubin, Daniel B ^b   Kodish, Eric ^c  

^a Maastricht University   (United States)

^b UNIVERSITY OF MICHIGAN LAW SCHOOL   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Enhancement; Ethics; Genetics; Research

Indexed keywords

ANABOLIC AGENT; BOTULINUM TOXIN A; DEXAMPHETAMINE; METHYLPHENIDATE;

ARTICLE; ATTENTION DEFICIT DISORDER; BREAST AUGMENTATION; CHILD CARE; CLINICAL RESEARCH; COGNITION; DRUG SURVEILLANCE PROGRAM; EXPERIMENTAL THERAPY; HEALTH CARE ORGANIZATION; HUMAN; KNOWLEDGE MANAGEMENT; MEDICAL ETHICS; MEDICAL PRACTICE; MEDICAL TECHNOLOGY; PARENTAL NOTIFICATION; PATIENT CARE; PATIENT PARTICIPATION; PATIENT SAFETY; PEDIATRICIAN; PRACTICE GUIDELINE; RESEARCH ETHICS; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT;

BIOMEDICAL ENHANCEMENT; BIOMEDICAL RESEARCH; CHILD; HUMANS; NONTHERAPEUTIC HUMAN EXPERIMENTATION; PEDIATRICS; UNITED STATES;

EID: 65949105504     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/0009922808330457     Document Type: Article

References (37)

1. Rubin R. Giving growth a synthetic hand: use of hormone sparks debate. Dallas Morning News. July 7, 1987 :A1.
2. American Academy of Aesthetic Plastic Surgeons, Cosmetic Surgery National Data Bank: Statistics. http://www.surgery.org/download/2006stats.pdf. Published 2006. Accessed November 25, 2007.
3. Weber RL A drug kids take in search of better grades. Christian Science Monitor. November 30, 2004 :Sect. 11.
4. Teter CJ, McCabe SE, Boyd CJ, Guthrie SK Illicit methylphenidate use in an undergraduate student sample: prevalence and risk factors. Pharmacotherapy. 2003 ; 23: 609-617. (Pubitemid 36546192)
5. McCabe SE, Teter CJ, Boyd CJ, Guthrie SK Prevalence and correlates of illicit methylphenidate use among 8th, 10th, and 12th grade students in the United States, 2001. J Adolesc Health. 2004 ; 35: 501-504. (Pubitemid 39576021)
6. Savulescu J. Justice, fairness, and enhancement. Ann N Y Acad Sci. 2006 ; 1093: 321-338. (Pubitemid 47092384)
7. Allen DB, Fost N. hGH For short stature: Ethical issues raised by expanded access. J Pediatr. 2004 ; 144: 648-652. (Pubitemid 38594768)
8. Johnson, T. What is 20/20 vision ? http://www.uihealthcare.com/topics/ medicaldepartments/ophthalmology/2020vision/index.html. Revised October 2004. Accessed June 7, 2007.
9. Apud JA, Mattay V., Chen J., et al. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology. 2007 ; 32: 1011-1020. (Pubitemid 46631983)
10. Kodish E. Ethics and Research With Children: A Case-Based Approach. Oxford, UK: Oxford University Press; 2005.
11. Ross LF Children in Medical Research: Access Versus Protection. Oxford, UK: Clarendon Press; 2006.
12. Field MJ, Behrman RE, eds. Ethical Conduct of Clinical Research Involving Children. Washington, DC: National Academies Press ; 2004.
13. Mehlman MJ, Berg JW Evaluating biomedical enhancement research: assessing risk and benefit and obtaining informed consent. Am J Law Med Ethics. In press.
14. Feinberg J. The child's right to an open future. In: Aiken W, LaFollette H, eds. Whose Child?: Children's Rights, Parental Authority, and State Power. Totowa, NJ: Rowman & Littlefield; 1980: 125-127.
15. Davis DS Genetic dilemmas and the child's right to an open future. Hastings Cent Rep. 1997 ; 27 (2). 7-15.
16. American Society of Plastic Surgeons. Policy statement on breast augmentation in teenagers. http://www.plasticsurgery.org/d.xml?comp=x983. Published 2004. Accessed December 30, 2008.
17. Gomez J. Use of performance-enhancing substances. Pediatrics. 2005 ; 115: 1103-1106.
18. Hartgens F., Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004 ; 34: 513-554. (Pubitemid 38981844)
19. National Institute on Drug Abuse (NIDA). NIDA InfoFacts: Steroids (Anabolic-Androgenic). http://www.drugabuse.gov/Infofacts/Steroids.html. Updated June 26, 2008. Accessed December 18, 2008.
20. Castellanos FX, Rapoport JL Effects of caffeine on development and behavior in infancy and childhood: a review of the published literature. Food Chem Toxicol. 2002 ; 40: 1235-1242. (Pubitemid 35247454)
21. Protection of Human Subjects: Code of Federal Regulations, 45 CFR §46.102(i)-46.407 (1983) (Rev. as of March 8, 1983).
22. Bokhari F., Mayes R., Scheffler RM An analysis of the significant variation in psychostimulant use across the U.S. Pharmacoepidemiol Drug Saf. 2005 ; 14: 267-275. (Pubitemid 40528856)
23. Robertson JA Genetic selection of offspring characteristics. Boston Univ Law Rev. 1996 ; 76: 421-482. (Pubitemid 126355540)
24. Coleman DL The legal ethics and pediatric research. Duke Law J. 2007 ; 57: 517-624.
25. Lidz CW, Appelbaum PS The therapeutic misconception: problems and solutions. Med Care. 2002 ; 40 (9 suppl). V55 - V63.
26. Berg JW Children and placebos. In: Kodish E, ed. Ethics and Research With Children: A Case-Based Approach. Oxford, UK: Oxford University Press. 2005: 294-309.
27. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (NCPHS). Research Involving Children: Report and Recommendations. Bethesda, MD: The Commission; 1977.
28. Field MJ, Behrman RE Institute of Medicine (U.S.). Committee on Clinical Research Involving Children. Ethical Conduct of Clinical Research Involving Children. Washington, DC: National Academies Press ; 2004.
29. Kopelman LM Children as research subjects: moral disputes, regulatory guidance, and recent court decisions. Mt Sinai J Med. 2006 ; 73: 596-604. (Pubitemid 43834194)
30. Shah S., Whittle A., Wilfond B., Gensler G., Wendler D. How do institutional review boards apply the federal risk and benefit standards for pediatric research ? JAMA. 2004 ; 291: 476-482. (Pubitemid 38129752)
31. Conrad P. Prescribing more psychotropic medications for children: what does the increase mean ? Arch Pediatr Adolesc Med. 2004 ; 158: 829-830. (Pubitemid 39025086)
32. Office for Human Research Protections. Children involved as subjects in research: guidance on the HHS 45 CFR 46.407 ("407") review process. http://www.hhs.gov/ohrp/children/guidance-407process.html. Published May 26, 2005. Accessed August 8, 2007.
33. Kopelman LM, Murphy TF Ethical concerns about federal approval of risky pediatric studies. Pediatrics. 2004 ; 113: 1783-1789. (Pubitemid 38697992)
34. Office for Human Research Protections. Effects of a single dose of dextroamphetamine in attention deficit hyperactivity disorder: a functional magnetic resonance study. http://www.hhs.gov/ohrp/children/adhd.html. Published October 19, 2005. Accessed August 8, 2007.
35. Vedantam S. Millions have misused ADHD stimulant drugs, study says. The Washington Post. February 25, 2006 :A09.
36. Office for Human Research Protections. 46.407 Review of protocol entitled "Effects of a single dose of dextroamphetamine in attention deficit hyperactivity disorder." http://www.hhs.gov/ohrp/panels/jreview01/withmemo. rtf. Published October 19, 2005. Accessed August 8, 2007.
37. Berg P. Potential biohazards of recombinant DNA molecules. In: Andrews LB, Mehlman MJ, Rothstein MA, eds. Genetics: Ethics Policy and Law. St. Paul, MN: West; 2002.